INNOVATE Corp. (VATE) NYSE
15.92
+0.025(+0.16%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
15.92
+0.025(+0.16%)
Currency In USD
| Previous Close | 15.89 |
| Open | 15.7 |
| Day High | 16.22 |
| Day Low | 15.37 |
| 52-Week High | 16.98 |
| 52-Week Low | 3.75 |
| Volume | 19,563.73 |
| Average Volume | 49,606 |
| Market Cap | 217.11M |
| PE | -3.75 |
| EPS | -4.24 |
| Moving Average 50 Days | 10.42 |
| Moving Average 200 Days | 6.38 |
| Change | 0.03 |
Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephrology (JASN)
GlobeNewswire Inc.
Feb 10, 2026 9:05 PM GMT
MediBeacon® Transdermal GFR System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic medical centers began in January 2026 NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- I
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
GlobeNewswire Inc.
Dec 16, 2025 1:05 PM GMT
MediBeacon® TGFRTM System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic medical centers begins in early 2026 NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Co
INNOVATE Corp. to Report Third Quarter 2025 Results on November 12th
GlobeNewswire Inc.
Oct 22, 2025 8:05 PM GMT
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the third quarter 2025 on Wednesday, November 12, 2025, after market close. The Com